Jonathan G Sham
Overview
Explore the profile of Jonathan G Sham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
354
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schnuck J, Chauhan S, Sham J
Hepatobiliary Surg Nutr
. 2024 Dec;
13(6):1062-1064.
PMID: 39669077
No abstract available.
2.
Dickerson L, Lipson T, Chauhan S, Allen G, Young B, Park J, et al.
J Surg Oncol
. 2024 Jul;
130(3):476-484.
PMID: 38990255
Background And Objectives: Few data exist to guide optimal communication practices for surgical oncologists. VitalTalk, an evidence-based communication skills training model for clinicians, offers the five-step ADAPT tool for discussing...
3.
Chauhan S, Vierra B, Park J, Pillarisetty V, Davidson G, Sham J
HPB (Oxford)
. 2024 Jul;
26(10):1229-1236.
PMID: 38971667
Background: Postoperative pancreatic fistulas lead to substantially increased morbidity, mortality, and healthcare costs after pancreatectomy. Studies have reported conflicting data on the role of prophylactic somatostatin analogs in the reduction...
4.
Park J, Lafaro K, Hagendoorn J, Melstrom L, Gerhards M, Gorgec B, et al.
J Am Coll Surg
. 2024 May;
239(1):61-67.
PMID: 38770933
Background: For open minor hepatectomy, morbidity and recovery are dominated by the incision. The robotic approach may transform this "incision dominant procedure" into a safe outpatient procedure. Study Design: We...
5.
Nakasone E, Bustillos H, Gui X, Konnick E, Sham J, Cohen S
Pancreas
. 2024 Mar;
53(6):e487-e491.
PMID: 38460151
Poorly differentiated pancreatic neuroendocrine carcinomas (pNECs) are rare, highly aggressive neoplasms. Frequently metastatic at diagnosis, prognosis is poor with median overall survival estimated to be less than 1 year. Although...
6.
Coveler A, Pillarisetty V, Koh W, Zhen D, Park J, King G, et al.
Pancreas
. 2023 Oct;
52(5):e282-e287.
PMID: 37782886
Objectives: Pancreatic ductal adenocarcinoma (PDA) is the third most common cause of cancer death in the United States. Most patients who undergo resection develop recurrence. Standard treatment confers a median...
7.
Goodsell K, Sharib J, Pillarisetty V, Sham J
Am J Surg
. 2023 Mar;
226(2):286-289.
PMID: 36959023
Surgery is considered for patients without metastatic disease and with resectable primary tumor. Pre-operatively, high quality imaging is reviewed to determine the likely extent of resection, specifically including the need...
8.
Clark N, Roberts E, Fedorenko C, Sun Q, Dubard-Gault M, Handford C, et al.
Ann Surg Oncol
. 2022 Nov;
30(3):1312-1326.
PMID: 36335273
Background: The National Comprehensive Cancer Network recommends genetic testing in patients with potentially hereditary breast, ovarian, pancreatic, and prostate cancers (HBOPP). Knowledge of genetic mutations impacts decisions about screening and...
9.
Diehl A, Hannan L, Zhen D, Coveler A, King G, Cohen S, et al.
Oncologist
. 2022 Sep;
27(12):1025-1033.
PMID: 36124727
Background: KRAS variant alleles may have differential biological properties which impact prognosis and therapeutic options in pancreatic ductal adenocarcinomas (PDA). Materials And Methods: We retrospectively identified patients with advanced PDA...
10.
Pillarisetty V, Abbasi A, Park J, Sham J
HPB (Oxford)
. 2022 Aug;
24(11):2029-2034.
PMID: 35953409
Background: Clinically relevant postoperative pancreatic fistula (CR-POPF) is a significant contributor to morbidity after pancreatectomy. Somatostatin analogues have shown variable efficacy in the prevention of CR-POPF. Lanreotide is a somatostatin...